Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.48%52 5-Year Yield-on-Cost % is 0.20 as of Aug. 10, 2026, which is 29% below its 10-year median of 0.28. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 150 Biotechnology companies, TCM Biotech International ranks worse than 90.67% on this metric.
TCM Biotech International (TPE:4169) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TCM Biotech International 5-Year Yield-on-Cost % Related Terms
TPE:4169 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, TCM Biotech International's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's 5-Year Yield-on-Cost % falls into.
TCM Biotech International 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
TCM Biotech International (TPE:4169) has a 5-Year Yield-on-Cost % of 0.20 as of Aug. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TCM Biotech International and its competitors. This is 29% below median its historical median of 0.28. Over the past decade, TCM Biotech International's 5-Year Yield-on-Cost % has ranged from 0.13 to 0.57. According to the industry distribution chart, TCM Biotech International ranks #136 out of 150 companies in the Biotechnology industry, placing it in the top 90.7%.
Is TCM Biotech International's 5-Year Yield-on-Cost % too high?
TCM Biotech International's current 5-Year Yield-on-Cost % of 0.20 is 29% below median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.57. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.60. TCM Biotech International's value of 0.20 is 87.5% below this industry median. Based on the distribution chart, TCM Biotech International ranks #136 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #136 out of 150 companies for 5-Year Yield-on-Cost %. This places TCM Biotech International in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. TCM Biotech International's value of 0.20 is 87.5% below this benchmark. Historically, TCM Biotech International's own 5-Year Yield-on-Cost % has ranged from 0.13 to 0.57 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 1.60, TCM Biotech International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current 5-Year Yield-on-Cost % of 0.20 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current 5-Year Yield-on-Cost % is 0.20, which is 29% below median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.20, which is 29% below median its 10-year median of 0.28 and 87.5% below the Biotechnology industry median of 1.60. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current 5-Year Yield-on-Cost % is 0.20 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
5-Year Yield-on-Cost %: 0.20 (29% below median its 10-year median of 0.28)
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
Industry Position: 87.5% below the Biotechnology median (#136 of 150)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
